Affigen LLC, of St. Louis, and CCRM, a Canadian not-for-profit organization funded by the Canadian government, the Province of Ontario and leading academic and industry partners to support regenerative medicines and associated enabling technologies, said they partnered to create and commercialize a closed platform for the production of individualized, tumor-identifying therapeutics for the treatment of a range of currently incurable cancers.